CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
实体瘤存在异常的物理和生化屏障,会妨碍嵌合抗原受体(CAR)T细胞疗法发挥作用。然而,人们对实体瘤微环境(例如缺氧)如何调节CAR-T 细胞功能尚缺乏了解。缺氧是许多晚期实体瘤的常见特征,可促使癌细胞和T细胞的代谢、表型及相互作用发生重塑。为了解CAR-T 细胞在实体瘤中的活性,并评估包含CAR-T 细胞的新型联合治疗效果,需要建立能够忠实模拟生理相关肿瘤微环境下CAR-T 细胞与实体瘤相互作用的体外模型。本文展示如何使用无需洁净室、基于微铣削的微器件建立缺氧三维(3-D)肿瘤模型,并评估CAR-T 细胞联合PD-1/PD-L1抑制的疗效。
Solid tumors contain abnormal physical and biochemical barriers that hinder chimeric antigen receptor (CAR) T cell therapies.
However, there is a lack of understanding on how the solid tumor microenvironment (e. g. hypoxia) modulates CAR-T cell function. Hypoxia is a common feature of many advanced solid tumors that contributes to reprogramming of cancer and T cell metabolism as well as their phenotypes and interactions.
To gain insights into the activities of CAR-T cells in solid tumors and to assess the effectiveness of new combination treatments involving CAR-T cells, in vitro models that faithfully reflect CAR-T cell-solid tumor interactions under physiologically relevant tumor microenvironment is needed.
Here we demonstrate how to establish a hypoxic 3-dimensional (3-D) tumor model using a cleanroom-free, micromilling-based microdevice and assess the efficacy of the combination treatment with CAR-T cells and PD-1/PD-L1 inhibition.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。